Abstract 1583P
Background
Gastric cancer with peritoneal metastases is associated with a dismal prognosis. Catheter-based intraperitoneal (IP) chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) are methods to deliver chemotherapy intraperitoneally leading to higher intraperitoneal concentrations of cytotoxic drugs, compared to intravenous administration. We reviewed the effectiveness of palliative intraperitoneal chemotherapy for patients with peritoneal metastases of gastric origin.
Methods
Embase, MEDLINE, Web of Science, and Cochrane were searched for articles on chemotherapy with palliative intent in patients with peritoneal metastases of gastric origin published up to April 2023. The primary outcome was overall survival. Secondary outcomes included toxicity and clinicopathological outcomes in patients that underwent conversion surgery. A Bayesian random effect model was used to calculate the pooled median overall survival (mOS).
Results
21 studies including 904 patients were retrieved, categorized in 3 treatment groups (IP docetaxel, IP paclitaxel and PIPAC). The pooled mOS for all intraperitoneal chemotherapy treatments was 14.2 months (95% CI: 10.8 – 17.7 months). The pooled hazard ratio of IP paclitaxel and docetaxel favored the combination of IP and systemic chemotherapy compared to systemic chemotherapy only (0.64, 95% CI: 0.47 – 0.86). mOS of IP paclitaxel, IP docetaxel and PIPAC with cisplatin and doxorubicin were respectively 18.3 months (95% CI: 14.0 – 22.7 months), 13.2 months (95% CI: 3.6 – 25.1 months) and 9.0 months (95% CI: 2.3 – 16.5 months). All treatment methods had a relatively safe toxicity profile. Conversion surgery was performed in 14% of the patients and a radical resection was achieved in 69%, with a mOS ranging from 24 to 33 months.
Conclusions
Patients with peritoneal metastases of gastric origin treated with intraperitoneal chemotherapy had a pooled median overall survival of 14.2 months and a pooled hazard ratio of 0.64 compared to systemic chemotherapy. Intraperitoneal chemotherapy, regardless of method of administration, is a safe treatment and conversion surgery is possible in a selected subset of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
B. Mostert: Financial Interests, Institutional, Research Grant: Sanofi, Pfizer, BMS; Financial Interests, Institutional, Speaker, Consultant, Advisor: Lilly, Servier; Financial Interests, Personal and Institutional, Speaker, Consultant, Advisor: BMS. B.P.L. Wijnhoven: Financial Interests, Institutional, Research Grant: BMS; Financial Interests, Institutional, Speaker, Consultant, Advisor: BMS. R.H. Mathijssen: Financial Interests, Institutional, Research Grant, Investigator-initiated research: Astellas, Bayer, Cristal Therapeutics, Pfizer, Roche, Sanofi, Servier, Boehringer Ingelheim, Novartis; Financial Interests, Institutional, Coordinating PI: Pamgene. All other authors have declared no conflicts of interest.
Resources from the same session
1590P - Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)
Presenter: Berenice Freile
Session: Poster session 22
1591P - Gastric cancer in young patients under 40 years: 5-year analyses of Georgian cancer registry
Presenter: Tamar Esakia
Session: Poster session 22
1617P - PRODIGE 29-UCGI 26 (NEOPAN): Quality of life results of a phase III randomised trial comparing chemotherapy with folfirinox (FFX) or gemcitabine (gem) in locally advanced pancreatic carcinoma (LAPC)
Presenter: Michel Ducreux
Session: Poster session 22
1618P - Durable efficacy of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced NRG1 fusion positive (NRG1+) pancreatic ductal adenocarcinoma (PDAC)
Presenter: Alison Schram
Session: Poster session 22
1620P - A phase II study of perioperative nalirifox in patients with resectable pancreatic ductal adenocarcinoma (rPDAC): Survival update and biomarkers analysis of the NITRO trial
Presenter: Davide Melisi
Session: Poster session 22
1621P - Efficacy and safety of erdafitinib in adults with pancreatic cancer and prespecified fibroblast growth factor receptor alterations (FGFRalt) in the phase II open-label: Single-arm RAGNAR trial
Presenter: Shubham Pant
Session: Poster session 22
1622P - D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)
Presenter: Shunsuke Kondo
Session: Poster session 22
1623P - Pelareorep (pela) + atezolizumab (atezo) and chemotherapy in first-line (1L) advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) patients: Results from the GOBLET study
Presenter: Dirk Arnold
Session: Poster session 22
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22